All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
The FDA to review annamycin Investigational New Drug application for R/R AML
On 29th August 2017, an Investigation New Drug (IND) application was submitted to the U.S. Food and Drug Administration (FDA) for the study of for annamycin, an anthracycline antibiotic, in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML).
Moleculin Biotech, a preclinical stage pharmaceutical company, are aiming to acquire approval of annamycin for R/R AML and, if the IND application is accepted and implemented (a decision is normally made within 30 days of submission), then the company will begin clinical trials in the last quarter of this year.
An IND application has been submitted previously by Moleculin Biotech for annamycin; however, the FDA requested some protocol revisions, as well as required some additional information and data related to Chemistry and Manufacturing Controls (CMC). This initial IND was withdrawn in order for Moleculin Biotech to gather and develop the required information and CMC data, which was submitted in the current IND application.
References